Agilent Technologies Inc. announced the contribution of Agilent AriaMx Real-Time qPCR instruments to five research hospitals in India to support their COVID-19 initiatives and help them serve the community at large
The aim is to create new genomics solutions that could combat cancer and advance market access
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
Subscribe To Our Newsletter & Stay Updated
